Hospital Dermatology
Review of Research in 2024-2025.
Alladeen A, Cho SK, Micheletti RG
CutisIn the feed 7 Jul 2026, issue 2026 Apr, added to PubMed 7 Jul 2026
Topics: Drug reactionsInfections & infestationsImaging, dermoscopy & AIPractice, education & research
Abstract
Dermatologists play a central role in the care of hospitalized patients with skin disease. This review summarizes research from January 2024 to December 2025 on severe cutaneous adverse drug reactions, emerging infectious diseases, hidradenitis suppurativa (HS), and inpatient dermatology workforce issues. Key developments include improved recognition and management of drug reactions; updated diagnostic and prognostic tools for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); and guidance for emerging infections such as measles, dengue, mpox, orthopoxviruses, and resistant dermatophytes. Evidence-based strategies for HS aim to reduce unnecessary admissions and optimize care. Workforce challenges, including limited access, high call burden, and potential for artificial intelligence (AI)-assisted diagnosis, are also highlighted. These findings emphasize the critical contributions of dermatologists to hospital-based care and provide emerging evidence to guide clinical practice.
Abstract from PubMed
PMID 42411892 · DOI 10.12788/cutis.1361